Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

	OMB APPR	ROVAL
	OMB Number:	3235-0287
	Estimated average bu	rden
ı	hours per response.	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LARSON JOHN WILLIAM						2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]									ionship of Reporting all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (spec		ner
(Last) (First) (Middle) C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR, 501 CANAL BLVD					04	3. Date of Earliest Transaction (Month/Day/Year) 04/28/2014 4. If Amendment, Date of Original Filed (Month/Day/Year)									below)		Filing	below)	
(Street) RICHMOND CA 94804				_									e) X						
(City)	(S	tate)	(Zip)																
		Tab	le I - I	Non-Der	ivativ	e Sec	curit	ties Ac	quire	d, D	isposed o	f, or Be	eneficial	ly O	wned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Year) if any		ion Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			nd 5) S B O		5. Amount of Securities Beneficially Owned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3	tion(s)			(Instr. 4)
Common Stock 04/28/20				2014	14		M		10,000	Α	\$5.66	228		3,160		D			
Common	ommon Stock 04/28/20			2014				S		10,000	D	\$13.4786	86 ⁽¹⁾ 218,160			D			
		-	Table								posed of, , converti			Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D) or Indirect (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$5.66	04/28/2014			M			10,000	(2	2)	06/09/2014	Common Stock	10,000	4	0.00	0		D	

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.29 to \$13.682, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

2. All shares underlying this option are vested and immediately exercisable.

Remarks:

/s/ Florence Tam, Attorney-in-**Fact**

04/30/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.